New combo tackles tough lymphoma: early safety trial shows promise
NCT ID NCT04049825
First seen Apr 09, 2026 · Last updated May 08, 2026 · Updated 4 times
Summary
This early-stage study tested a new drug (OPB-111077) added to two standard chemotherapy drugs (bendamustine and rituximab) in 36 adults with a type of blood cancer called diffuse large B-cell lymphoma that had returned or stopped responding to treatment. The main goal was to see if the combination was safe and tolerable. Researchers monitored side effects and looked for the highest safe dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yamagata University Hospital
Yamagata, Japan
Conditions
Explore the condition pages connected to this study.